Synthetic Biologics Inc SYN:NYSE American

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:45 PM EDT
0.50quote price arrow up+0.00 (+0.51%)
Volume
20,508
Close
0.4945quote price arrow up+0.0055 (+1.12%)
Volume
1,296,787
52 week range
0.26 - 1.70
Loading...
  • Open0.4808
  • Day High0.5096
  • Day Low0.48
  • Prev Close0.489
  • 52 Week High1.70
  • 52 Week High Date01/05/21
  • 52 Week Low0.26
  • 52 Week Low Date10/02/20

Key Stats

  • Market Cap65.29M
  • Shares Out132.04M
  • 10 Day Average Volume2.48M
  • Dividend-
  • Dividend Yield-
  • Beta1.84
  • YTD % Change29.11

KEY STATS

  • Open0.4808
  • Day High0.5096
  • Day Low0.48
  • Prev Close0.489
  • 52 Week High1.70
  • 52 Week High Date01/05/21
  • 52 Week Low0.26
  • 52 Week Low Date10/02/20
  • Market Cap65.29M
  • Shares Out132.04M
  • 10 Day Average Volume2.48M
  • Dividend-
  • Dividend Yield-
  • Beta1.84
  • YTD % Change29.11

RATIOS/PROFITABILITY

  • EPS (TTM)-0.44
  • P/E (TTM)-1.12
  • Fwd P/E (NTM)-5.49
  • EBITDA (MRQ)-9.836M
  • ROE (MRQ)-59.22%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/08/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Synthetic Biologics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. The Company's lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic...
Jeffrey Kraws
Non-Executive Chairman
Steven Shallcross
Chief Executive Officer
Address
9605 Medical Center Dr Ste 270
Rockville, MD
20850-6382
United States